Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model.

[1]  J. Prieto,et al.  Immunological landscape and immunotherapy of hepatocellular carcinoma , 2015, Nature Reviews Gastroenterology &Hepatology.

[2]  Guangfu Li,et al.  Immune-based Therapy Clinical Trials in Hepatocellular Carcinoma , 2015, Journal of clinical & cellular immunology.

[3]  D. Morgensztern,et al.  Immunotherapy for non-small cell lung cancer: are we on the cusp of a new era? , 2015, Expert review of clinical immunology.

[4]  Joon-Oh Park,et al.  Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. , 2015, The Lancet. Oncology.

[5]  S. Kim,et al.  Reply to "The problem of the most appropriate curative treatment for hepatocellular carcinoma. When to embolize? When to operate?". , 2015, Journal of hepatology.

[6]  S. El-Etreby,et al.  Guide for diagnosis and treatment of hepatocellular carcinoma. , 2015, World journal of hepatology.

[7]  T. Yau,et al.  Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  X. Wang,et al.  Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches , 2015, Gut.

[9]  J. Marchand,et al.  TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice , 2014, Gut.

[10]  B. Sangro,et al.  Combined Immunostimulatory Monoclonal Antibodies Extend Survival in an Aggressive Transgenic Hepatocellular Carcinoma Mouse Model , 2013, Clinical Cancer Research.

[11]  Michelle L. West,et al.  CC chemokine receptor 8 potentiates donor Treg survival and is critical for the prevention of murine graft-versus-host disease. , 2013, Blood.

[12]  P. Galle,et al.  Facing the dawn of immunotherapy for hepatocellular carcinoma. , 2013, Journal of hepatology.

[13]  G. Karaca,et al.  Smoothened is a master regulator of adult liver repair. , 2013, The Journal of clinical investigation.

[14]  E. Wagner,et al.  Mouse models for liver cancer , 2013, Molecular oncology.

[15]  C. Loddenkemper,et al.  Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance. , 2013, The Journal of clinical investigation.

[16]  John D Lambris,et al.  Complement inhibition in cancer therapy. , 2013, Seminars in immunology.

[17]  T. Luedde,et al.  Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer , 2012, Gut.

[18]  S. S. Zhang,et al.  Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model , 2012, Hepatology.

[19]  C. Drake,et al.  Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma , 2011, Clinical Cancer Research.

[20]  C. Punt,et al.  Cancer immunotherapy – revisited , 2011, Nature Reviews Drug Discovery.

[21]  N. McDonnell,et al.  Doxycycline Ameliorates the Susceptibility to Aortic Lesions in a Mouse Model for the Vascular Type of Ehlers-Danlos Syndrome , 2011, Journal of Pharmacology and Experimental Therapeutics.

[22]  R. Thimme,et al.  Potential of immunotherapy for hepatocellular carcinoma. , 2011, Journal of hepatology.

[23]  J. Bruix,et al.  Management of hepatocellular carcinoma: An update , 2011, Hepatology.

[24]  S. Groshen,et al.  Portable Filter-Based Microdevice for Detection and Characterization of Circulating Tumor Cells , 2010, Clinical Cancer Research.

[25]  C. Nanni,et al.  A novel model of CCl4-induced cirrhosis with ascites in the mouse. , 2009, Journal of hepatology.

[26]  W. Pan,et al.  Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients , 2009, International journal of cancer.

[27]  C. Divino,et al.  The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. , 2009, Cancer research.

[28]  J. Bluestone,et al.  Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways , 2008, Immunological reviews.

[29]  P. Brossart,et al.  Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. , 2008, Blood.

[30]  A. Chakraborty,et al.  Fusion of tumour cells with bone marrow-derived cells: a unifying explanation for metastasis , 2008, Nature Reviews Cancer.

[31]  Siyang Zheng,et al.  Membrane microfilter device for selective capture, electrolysis and genomic analysis of human circulating tumor cells. , 2007, Journal of chromatography. A.

[32]  P. Paterlini-Bréchot,et al.  Circulating tumor cells (CTC) detection: clinical impact and future directions. , 2007, Cancer letters.

[33]  C. Trautwein,et al.  CB1 cannabinoid receptor antagonism: A new strategy for the treatment of liver fibrosis , 2007, Hepatology.

[34]  T. Schell,et al.  Early Immunization Induces Persistent Tumor-Infiltrating CD8+ T Cells against an Immunodominant Epitope and Promotes Lifelong Control of Pancreatic Tumor Progression in SV40 Tumor Antigen Transgenic Mice1 , 2006, The Journal of Immunology.

[35]  Weiping Zou,et al.  Immunosuppressive networks in the tumour environment and their therapeutic relevance , 2005, Nature Reviews Cancer.

[36]  S. Davies,et al.  Compromised lymphocytes infiltrate hepatocellular carcinoma: The role of T‐regulatory cells , 2005, Hepatology.

[37]  L. Butterfield.  Immunotherapeutic strategies for hepatocellular carcinoma. , 2004, Gastroenterology.

[38]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[39]  M. J. Tevethia,et al.  In Vivo Ligation of CD40 Enhances Priming Against the Endogenous Tumor Antigen and Promotes CD8+ T Cell Effector Function in SV40 T Antigen Transgenic Mice1 , 2003, The Journal of Immunology.

[40]  M. Nishimura,et al.  Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. , 2002, Immunity.

[41]  D. Gabrilovich,et al.  Immature myeloid cells and cancer-associated immune suppression , 2002, Cancer Immunology, Immunotherapy.

[42]  Nicholas R. English,et al.  Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer1 , 2001, The Journal of Immunology.

[43]  Yasuo Ohashi,et al.  Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial , 2000, The Lancet.

[44]  Cheryl Jorcyk,et al.  The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma , 2000, Oncogene.

[45]  A. Ribas,et al.  α-Fetoprotein-specific Genetic Immunotherapy for Hepatocellular Carcinoma , 1999 .

[46]  P. Klenerman,et al.  Immune surveillance against a solid tumor fails because of immunological ignorance. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[47]  F. Chisari,et al.  Immune Pathogenesis of Hepatocellular Carcinoma , 1998, The Journal of experimental medicine.

[48]  M. Kojiro,et al.  Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration , 1998, Hepatology.

[49]  J. Green,et al.  Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[50]  J. Mullins,et al.  T antigen expression and tumorigenesis in transgenic mice containing a mouse major urinary protein/SV40 T antigen hybrid gene. , 1989, The EMBO journal.

[51]  E. Farber.  The multistep nature of cancer development. , 1984, Cancer research.

[52]  G. L. Levi Sandri,et al.  The problem of the most appropriate curative treatment for hepatocellular carcinoma. When to embolize? When to operate? , 2015, Journal of hepatology.

[53]  Riccardo Lencioni,et al.  Design and endpoints of clinical trials in hepatocellular carcinoma. , 2008, Journal of the National Cancer Institute.

[54]  A. Ribas,et al.  Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma. , 1999, Cancer research.